ORDER NOW!
Contact your Dechra or Distributor Representative or call (866) 683-0660.
Rapid and effective fever control1,2*
In a clinical study, Zimeta significantly reduced fever in horses with naturally occurring disease, including respiratory disease, when checked 6 hours post-dosing.2
*When administered according to label directions
In a study, Zimeta reduced fever ≥2.0°F, or the temperature decreased to normal (≤101.0°F), in 74.8% of treated horses compared to 20.6% in the placebo group when checked at 6 hours.1
In a clinical pilot study of eight horses, Zimeta significantly reduced fever in horses with naturally occurring disease following one dose of Zimeta.3
This pilot study supports the clinical field study demonstrating effective fever control at 6 hours post-dosing.
In a clinical crossover study, horses with naturally occurring fever were administered either Zimeta or a placebo. Twenty-four hours after the initial dose, qualifying (febrile) horses received the opposite treatment. During both phases of the study, only Zimeta-treated horses demonstrated statistically significant reduction in fever.4
This pilot study supports the clinical field study demonstrating effective fever control at 6 hours post-dosing.
Sign up to receive future communications about Zimeta
For more information:
Contact your Dechra Representative
or call (866) 683-0660.
To place an order now:
Contact your Dechra Representative, Distributor Representative, or call (866) 683-0660.
Zimeta is indicated for the control of pyrexia in horses
Important Safety Information
As with all drugs, side effects may occur. Zimeta®(dipyrone injection) should not be given more frequently than every 12 hours due to the prolongation of prothrombin time (PT) and associated clinical signs of coagulopathy. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals. Not for use in humans, avoid direct contact with skin and keep out of reach of children. Care should be taken to avoid accidental self-injection and routine precautions should be used when handling and using loaded syringes as dipyrone can cause a deficiency in specific white blood cells in humans. Prior to use, horses should undergo a thorough history and physical examination by a veterinarian. Monitor for signs of abnormal bleeding and use caution in horses at risk for hemorrhage. Concurrent use with other NSAIDs, corticosteroids and drugs associated with kidney toxicity, should be avoided. Safety has not been evaluated in horses less than three years of age, horses used for breeding, or in pregnant or lactating mares. As a class, NSAIDs may be associated with gastrointestinal, kidney, and liver toxicity. The most common adverse reactions observed during clinical trials were elevated glucose conversion enzymes, decreased blood protein, gastric ulcers, inflamed or reddened lining of the right dorsal colon, and increased clotting times. Please see product insert for full prescribing information or visit www.dechra-us.com.
As with all drugs, side effects may occur. Zimeta®(dipyrone injection) should not be given more frequently than every 12 hours due to the prolongation of prothrombin time (PT) and associated clinical signs of coagulopathy. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals. Not for use in humans, avoid direct contact with skin and keep out of reach of children. Care should be taken to avoid accidental self-injection and routine precautions should be used when handling and using loaded syringes as dipyrone can cause a deficiency in specific white blood cells in humans. Prior to use, horses should undergo a thorough history and physical examination by a veterinarian. Monitor for signs of abnormal bleeding and use caution in horses at risk for hemorrhage. Concurrent use with other NSAIDs, corticosteroids and drugs associated with kidney toxicity, should be avoided. Safety has not been evaluated in horses less than three years of age, horses used for breeding, or in pregnant or lactating mares. As a class, NSAIDs may be associated with gastrointestinal, kidney, and liver toxicity. The most common adverse reactions observed during clinical trials were elevated glucose conversion enzymes, decreased blood protein, gastric ulcers, inflamed or reddened lining of the right dorsal colon, and increased clotting times. Please see product insert for full prescribing information or visit www.dechra-us.com.
References
- Zimeta® (dipyrone injection) [package insert], Rev. 12/2020.
- Data on file. REF-0155. Dechra Ltd.
- Data on file. REF-0167. Dechra Ltd.
- Data on file. REF-0269. Dechra Ltd.
Zimeta® is a registered trademark of Kindred Biosciences, Inc. in the United States and/or other countries.
© 2021 Dechra Veterinary Products, LLC. All rights reserved.
